Verastem Oncology revenue was $88.52 m in FY, 2020 which is a (407.1%) year over year increase from the previous period.
Verastem Oncology revenue breakdown by business segment: 17.2% from Product Revenue, 79.1% from Sale of COPIKTRA License and 3.7% from Other
|FY, 2020||FY, 2019||FY, 2018|
|Product Revenue||$15.23 m||$12.34 m||$1.72 m|
|License and Collaboration Revenue||$2.91 m||$5.12 m||$25 m|
|Sale of COPIKTRA License||$70 m|
|Transition Services Revenue||$372 k|
Craft can deliver 250+ data points of financial, operating, and human capital indicators on companies via API.